Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2021-02-11 Sale | 2021-02-16 7:35 pm | Monopar Therapeutics | MNPR | Tactic Pharma LLC Mazar Andrew Paul Robinson Chandler O'Halloran Thomas V. Brown Michael J 10% Owner | 125,000 | $14.64 | $1,830,620 | 4,277,940 (Indirect Direct) | View |
| 2019-12-18 Purchase | 2019-12-20 6:33 pm | Monopar Therapeutics | MNPR | Tactic Pharma LLC Mazar Andrew Paul Robinson Chandler O'Halloran Thomas V. Brown Michael J 10% Owner | 125,000 | $8 | $1,000,000 | 4,402,940 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2022-03-31 Exercise | 2022-04-01 5:28 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 1,606 | $0 | 4,388,857 (Direct) | View |
| 2022-03-31 Tax Withholding | 2022-04-01 5:28 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 471 | $2.55 | 4,388,857 (Direct) | View |
| 2022-02-02 Option Award | 2022-02-04 7:38 pm | N/A 2032-02-01 | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 156,125 | $0 | 179,272 (Direct) | View |
| 2022-01-01 Exercise | 2022-01-04 2:49 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 1,937 | $0 | 4,302,804 (Direct) | View |
| 2022-01-01 Tax Withholding | 2022-01-04 2:49 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 671 | $3.21 | 4,302,804 (Direct) | View |
| 2021-12-31 Exercise | 2022-01-04 2:40 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 1,606 | $0 | 4,316,937 (Direct) | View |
| 2021-12-31 Tax Withholding | 2022-01-04 2:40 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 556 | $3.21 | 4,316,937 (Direct) | View |
| 2021-09-30 Exercise | 2021-10-01 7:31 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 1,606 | $0 | 4,317,493 (Direct) | View |
| 2021-09-30 Tax Withholding | 2021-10-01 7:31 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 471 | $4.87 | 4,317,493 (Direct) | View |
| 2021-06-30 Exercise | 2021-07-02 5:11 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 3,212 | $0 | 4,317,964 (Direct) | View |
| 2021-06-30 Tax Withholding | 2021-07-02 5:11 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 942 | $5.89 | 4,317,964 (Direct) | View |
| 2021-01-26 Option Award | 2021-01-28 6:49 pm | N/A 2031-01-25 | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 61,774 | $0 | 67,585 (Direct) | View |
| 2021-01-01 Exercise | 2021-01-05 5:38 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 1,937 | $0 | 4,424,020 (Direct) | View |
| 2021-01-01 Tax Withholding | 2021-01-05 5:38 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 671 | $6.12 | 4,424,020 (Direct) | View |
| 2020-01-31 Option Award | 2020-02-20 8:55 pm | N/A N/A | Monopar Therapeutics | MNPR | Mazar Andrew Paul Chief Scientific Officer | 39,941 | $0 | 39,941 (Direct) | View |